72966 - Research and Development of Recombinant and Biological Drugs

Academic Year 2021/2022

Learning outcomes

Aim of the course is the use of microorganisms in the industrial fermentative production of pharmaceutical compounds

Course contents

Use of recombinant bacteria and yeasts for the production of hormones, fibrinolytic agents, cytokines and recombinant toxins. Industrial processes and downstream. Development of recombinant organisms for the production of biologicals, such as chimeric and humanized monoclonal antibodies. Protein engineering to improve the pharmacokinetics of recombinant proteins. Targeting of drugs by immune-proteins.

Readings/Bibliography

Papers and reviews suggested by the teacher

Teaching methods

Lessons will address the development and employment of genetically modified organisms in the pharmaceutical industrial sector.

Assessment methods

The assessment of learning takes place through final oral examination, which tends to ensure the acquisition of knowledge on topics related to the main learning objectives of the course:
- Industrial use of microorganisms for the production of primary and secondary metabolites of pharmaceutical interest;
- Use of recombinant microorganisms for the industrial production of heterologous proteins of pharmaceutical interest;
- Approaches of protein engineering to modify drug-kinetic characteristics of recombinant proteins;
- Development of biologics.

Teaching tools

PC, projector

Office hours

See the website of Patrizia Brigidi

SDGs

Good health and well-being

This teaching activity contributes to the achievement of the Sustainable Development Goals of the UN 2030 Agenda.